• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections

Opinion
Video

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.

Video content above is prompted by the following:

  • What is the key data that led to the FDA approval of Rebyota for recurrent C difficile infection?
  • Who are the target patient populations for Rebyota?
Related Videos
1 expert is featured in this series.
Miriam Freimer, MD
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Dr John Mascarenhas
5 experts are featured in this series
2 experts in this video
Related Content
emergency department | Image Credit: chrisdorney - stock.adobe.com

Prolonged ED Stays, Boarding Times Among Older Adults Underscore Systemic Hospital Strain

June 30th 2025
Article

The recent increase in prolonged emergency department (ED) stays and boarding times for older adults reveals systemic challenges in US hospital care.

Read More

managed care cast logo

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

December 23rd 2024
Podcast

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

June 27th 2025
Article

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

June 25th 2025
Article

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Read More

Marginal zone lymphoma | Image: Atlas of Hematological Cytology

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

June 24th 2025
Article

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.